国药集团一致药业股份有限公司 2014 年年度报告全文
China National Accord Medicines Corporation Ltd.
Annual Report 2014
March 2015
1
国药集团一致药业股份有限公司 2014 年年度报告全文
Section I. Important Notice, Contents and Paraphrase
Board of Directors, Supervisory Committee, all directors, supervisors and senior
executives of China National Accord Medicines Corporation Ltd. (hereinafter
referred to as the Company) hereby confirm that there are no any fictitious statements,
misleading statements, or important omissions carried in this report, and shall take all
responsibilities, individual and/or joint, for the reality, accuracy and completion of
the whole contents.
Other directors attending the Meeting for annual report deliberation except for the
followed:
Name of director absent Title for absent director Reasons for absent Attorney
Wei Yulin director Official business Li Zhiming
The profit distribution plan that deliberated and approved by the Board is: based on
total stock issued 362,631,943 shares, distributed 2.00 Yuan (tax included) bonus in
cash for every 10-share hold by all shareholders, 00 shares bonus issued (tax included)
and no capitalizing of common reserves carried out.
Yan Zhigang, Principal of the Company, Wei Pingxiao, person in charger of
accounting works and Zhou Feifei, person in charge of accounting organ (accounting
principal) hereby confirm that the Financial Report of 2014 Annual Report is
authentic, accurate and complete.
2
国药集团一致药业股份有限公司 2014 年年度报告全文
Contents
Annual Report 2014 ........................................................................................................................... 1
Section I Important Notice, Contents and Paraphrase ................................................................. 2
Section II Company Profile ............................................................................................................... 7
Section III Accounting data and summary of finnaical indexes .................................................. 9
Section IV Report of the Board of Directors ............................................................................... 13
Section V Important Events .......................................................................................................... 35
Section VI Changes in shares and particular about shareholders .............................................. 49
Section VII Preferred Stock…………………………………………………………………….60
Section VIII Particulars about Directors, Supervisors,Senior Executives and Employees ...... 60
Section IX Corporate Governance ............................................................................................... 773
Section X Internal Control .............................................................................................................. 80
Section XI Financial Report ............................................................................................................ 83
Section XII Documents available for reference ........................................................................... 215
3
国药集团一致药业股份有限公司 2014 年年度报告全文
Paraphrase
Refers
Items Contents
to
Listed Company, Company, the Company, Refers
China National Accord Medicines Corporation Ltd.
Sinopharm Accord, the Group to
Refers Sinopharm Group Co., Ltd.; Controlling shareholder of the
Sinopharm Holding
to Company
Refers
“Twelfth Five-Year” Year of 2011 to 2015
to
Refers
Company Law Company Law of the People’s Republic of China
to
Refers
Securities Law Securities Law of the People’s Republic of China
to
Yuan, 10 thousand Yuan, 100 million Refers
RMB, RMB 10 thousand, RMB 100 million
Yuan to
Terminology:
Refers
Direct selling A sales method of selling drug to the hospital directly
to
Refers
GMP certificate Good Manufacture Practice of Drugs certificate
to
Refers
GSP certificate Good Supply Practice certificate
to
Refers That is CMS, and information system processing workflow &
Supply Chain Management
to procurement, inventory & sales documents
Abbreviation
Refers
Sinopharm China National Pharmaceutical Group Corporation
to
Refers
Sinopharm (CNCM LTD) China National Medicines Corporation Ltd.
to
Refers
Sinopharm Holding Guangzhou Sinopharm Holding Guangzhou Co., Ltd.
to
Refers
Sinopharm Holding Guangxi Sinopharm Holding Guangxi Co., Ltd.
to
Refers
Sinopharm Holding Liuzhou Sinopharm Holding Liuzhou Co., Ltd.
to
Refers
Zhijun Pharmaceutical Shenzhen Zhijun Pharmaceutical Co., Ltd.
to
Refers
China National Zhijun (Suzhou) China National Zhijun (Suzhou) Pharmaceutical Co., Ltd.
to
4
国药集团一致药业股份有限公司 2014 年年度报告全文
Refers
Zhijun Pharmacy Trade Shenzhen Zhijun Pharmacy Trade Co., Ltd.
to
Refers
Sinopharm Shenzhen Chinese Medicine Sinopharm Holding Shenzhen Chinese Medicine Co., Ltd.
to
Refers
Main Luck Pharmaceutical Shenzhen Main Luck Pharmaceuticals Inc.
to
5
国药集团一致药业股份有限公司 2014 年年度报告全文
Major Risk Warning
It is likely to existing risks in aspect of industrial competition, operation&
management, market and national policy, and majority investors are advised to
exercise caution of investment risks.
6
国药集团一致药业股份有限公司 2014 年年度报告全文
Section II Company profile
I. Company information
Short form of the stock Sinopharm Accord ; Accord B Stock code 000028, 200028
Stock exchange for listing Shenzhen Stock Exchange
Name of the Company (in
国药集团一致药业股份有限公司
Chinese)
Short form of the Company
国药一致
(in Chinese)
Foreign name of the
China National Accord Medicines Corporation Ltd.
Company(if applicable)
Short form of foreign name
of the Company(if Sinopharm Accord
applicable)
Legal representative Yan Zhigang
Accord Pharm. Bldg., No. 15, Ba Gua Si Road, Futian District, Shenzhen, Guangdong
Registrations add.
Province
Code for registrations add 518029
Accord Pharm. Bldg., No. 15, Ba Gua Si Road, Futian District, Shenzhen, Guangdong
Offices add.
Province
Codes for office add. 518029
Company’s Internet Web
http://www.szaccord.com.cn
Site
E-mail investor@szaccord.com.cn
II. Person/Way to contact
Secretary of the Board Rep. of security affairs
Name Chen Changbing
Accord Pharm. Bldg., No. 15, Ba Gua
Contact add. Si Road, Futian District, Shenzhen,
Guangdong Province
Tel. +(86)755 25875195
Fax. +(86)755 25195435
0028@szaccord.com.cn;
E-mail
gyyz0028@sinopharm.com
III. Information disclosure and preparation place
Securities Times; China Securities Journal; Hong Kong Commercial
Newspaper appointed for information disclosure
Daily
7
国药集团一致药业股份有限公司 2014 年年度报告全文
Website for annual report publish appointed by
http://www.szse.cn; http://www.cninfo.com.cn
CSRC
Preparation place for annual report Secretariat of the Board of Directors
IV. Registration changes of the Company
Registration NO.
Date for Place for No. of taxation
for enterprise legal Organization code
registration registration registration
license
Initial registration 1986-08-02 Shenzhen. P.R.C 4403011001677 440301192186267 19218626-7
Registration at end
2012-11-06 Shenzhen. P.R.C 440301103040048 440301192186267 19218626-7
of report period
V. Other relevant information
CPA engaged by the Company
Name of CPA Pricewaterhouse Zhongtian Certified Public Accountants Co., Ltd. (LLP)
11/Floor,PWC Center, Building 2#, Corporate Avenue, No.202 Hubin Rd., Luwan
Offices add. for CPA
District, Shanghai, P.R.C
Signing Accountants Chen Yuntao, Tan Pianpian
Sponsor engaged by the Company for performing continuous supervision duties in reporting period
√Applicable □Not applicable
Name of sponsor Continuous supervision
Name of the sponsor Offices add. for the sponsor
representative period
27/F-28/F, Building 2,
China International Capital International Trade
Chen Jie, Ru Tao 2014 -2016
Corporation Limited Mansion, No.1 Jianguomen
Outer Street, Beijing
Financial consultant engaged by the Company for performing continuous supervision duties in reporting period
□ Applicable √ Not applicable
8
国药集团一致药业股份有限公司 2014 年年度报告全文
Section III. Accounting data and summary of financial indexes
I. Main accounting data and financial indexes
Whether it has retroactive adjustment or re-statement on previous accounting data for accounting policy changed and
accounting error correction or not
√ Yes □ No
Changes over
2013
last year
Before the After the After the Before the After the
adjustment adjustment adjustment adjustment adjustment
Operating income 23,954,331,028. 21,199,466,399. 21,199,466,399. 18,011,759,1 18,011,759,1
12.99%
(RMB) 05 21 21 78.26 78.26
Net profit attributable to
475,792,491. 475,792,491.
shareholders of the 652,497,176.03 520,488,198.80 520,488,198.80 25.36%
12
listed company(RMB)
Net profit attributable to
shareholders of the
448,238,374. 448,238,374.
listed company after 611,245,652.69 505,828,794.23 505,828,794.23 20.84%
59
deducting non-recurring
gains and losses(RMB)
Net cash flow arising
323,955,332. 323,955,332.
from operating -796,697,032.43 465,028,099.83 465,028,099.83 -271.32%
76
activities(RMB)
Basic earnings per
1.90 1.81 1.81 4.97% 1.65 1.65
share (RMB/Share)
Diluted earnings per
1.90 1.81 1.81 4.97% 1.65 1.65
share (RMB/Share)
Weighted average
16.41% 26.00% 26.00% -9.59% 30.51% 30.51%
ROE
Changes over
End of 2013 end of last End of 2012
End of 2014 year
Before the After the After the Before the After the
adjustment adjustment adjustment adjustment adjustment
12,828,941,540. 11,057,896,941. 11,057,896,941. 9,295,839,93 9,295,839,93
Total assets (RMB) 16.02%
90 31 31 9.64 9.64
Net assets attributable
to shareholder of 4,764,607,822.0 2,244,757,658.0 2,244,757,658.0 1,775,943,02 1,775,943,02
112.25%
listed 9 3 3 8.96 8.96
company(RMB)
9
国药集团一致药业股份有限公司 2014 年年度报告全文
II. Difference of the accounting data under accounting rules in and out of China
1. Difference of the net profit and net assets disclosed in financial report, under both IAS (International
Accounting Standards) and Chinese GAAP (Generally Accepted Accounting Principles)
□ Applicable √ Not applicable
The Company had no difference of the net profit or net assets disclosed in financial report, under either IAS
(International Accounting Standards) or Chinese GAAP (Generally Accepted Accounting Principles) in the period.
2. Difference of the net profit and net assets disclosed in financial report, under both foreign accounting
rules and Chinese GAAP (Generally Accepted Accounting Principles)
□ Applicable √ Not applicable
The Company had no difference of the net profit or net assets disclosed in financial report, under either foreign
accounting rules or Chinese GAAP (Generally Accepted Accounting Principles) in the period.
III. Items and amounts of extraordinary profit (gains)/loss
√Applicable □Not applicable
In RMB
Item 2014 2013 2012 Note
Mainly because Subsidiary --
Gains/losses from the disposal of
Sinopharm Holding Liuzhou,
non-current asset (including the -8,347,047.7
2,262,989.96 3,029,150.67 has a new property changed
write-off that accrued for impairment of
due to the relocation by
assets)
government
Mainly due to the follow
subsidies received: the
enterprise supporting fund
RMB 6.06 million allocated
from Nanning Economic and
Technological Development
Governmental subsidy reckoned into Zone, medicine reserves
current gains/losses (not including the appropriate RMB 3 million,
subsidy enjoyed in quota or ration 23,465,438.4 57,227,812.3 special funds RMB 2.28
31,534,869.05
according to national standards, which 2 3 million from Shenzhen High
are closely relevant to enterprise’s
